Plain-English translation of NCT06850727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new oral medication called for people with moderate to severe ulcerative colitis who have not had good results with other treatments. The medication is taken by mouth twice daily. The trial will also look at whether this treatment can work better when followed by another existing medication called .
Many people with ulcerative colitis don't respond well enough to current treatment options, or they can't tolerate them. This trial is exploring whether this new medication could offer another choice for patients who need better control of their symptoms.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily as part of one of three treatment groups. Some participants will receive an initial open-label phase (everyone knows they're getting the medication), while others will be randomly assigned to different dose levels. After completing the initial treatment period, you may continue to a second part of the study where you receive a follow-up medication. Throughout the trial, you'll have visits to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia